Illumina (ILMN) Set to Announce Quarterly Earnings on Monday

Illumina (NASDAQ:ILMN - Get Free Report) is set to post its quarterly earnings results after the market closes on Monday, November 4th. Analysts expect Illumina to post earnings of $0.87 per share for the quarter. Illumina has set its FY 2024 guidance at 3.800-3.950 EPS.Individual interested in listening to the company's earnings conference call can do so using this link.

Illumina (NASDAQ:ILMN - Get Free Report) last posted its quarterly earnings data on Tuesday, August 6th. The life sciences company reported $0.36 EPS for the quarter, beating the consensus estimate of $0.12 by $0.24. Illumina had a negative net margin of 68.73% and a positive return on equity of 3.08%. The business had revenue of $1.11 billion during the quarter, compared to analyst estimates of $1.09 billion. During the same quarter last year, the firm posted $0.32 earnings per share. The business's revenue for the quarter was down 5.4% compared to the same quarter last year. On average, analysts expect Illumina to post $4 EPS for the current fiscal year and $4 EPS for the next fiscal year.

Illumina Stock Up 1.5 %

Shares of NASDAQ ILMN traded up $2.08 during midday trading on Monday, hitting $144.03. The company's stock had a trading volume of 853,361 shares, compared to its average volume of 1,997,165. The business's fifty day simple moving average is $134.53 and its two-hundred day simple moving average is $121.57. The company has a debt-to-equity ratio of 1.04, a current ratio of 1.11 and a quick ratio of 0.86. Illumina has a 1 year low of $89.00 and a 1 year high of $151.40. The firm has a market capitalization of $22.94 billion, a price-to-earnings ratio of -7.41 and a beta of 1.15.

Analyst Ratings Changes

ILMN has been the topic of several analyst reports. Hsbc Global Res raised shares of Illumina from a "hold" rating to a "strong-buy" rating in a report on Thursday, October 17th. StockNews.com initiated coverage on shares of Illumina in a research report on Thursday, August 29th. They issued a "buy" rating on the stock. Stephens restated an "overweight" rating and set a $170.00 target price on shares of Illumina in a research report on Wednesday, July 10th. TD Cowen upgraded shares of Illumina from a "hold" rating to a "buy" rating and boosted their price objective for the stock from $126.00 to $144.00 in a research report on Wednesday, August 14th. Finally, Daiwa America upgraded shares of Illumina to a "strong-buy" rating in a research report on Friday, August 16th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating, fourteen have issued a buy rating and two have assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, Illumina currently has a consensus rating of "Moderate Buy" and a consensus price target of $154.33.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.